The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis;2) vaccines to prevent HIV;and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will continue its productivity through active engagement with a diverse host of at risk and HIV-impacted communities, participation in high impact, ground-breaking clinical research studies, efficient management of resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU includes CRSs and personnel that have long term and productive involvement with three of the research networks;the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their network affiliations include: Northwestern University (adult HIV therapeutic strategies);University of Illinois Chicago (vaccines to prevent HIV, integrated HIV prevention). Rush University (adult HIV therapeutic strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health &Wellness Center (adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of the major urban HIV epicenters.
The aims of this proposal are: development, implementation and adaptation of the clinical research program of the 1) Adult HIV Therapeutics Strategy, Network, 2) the Vaccines to Prevent HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional, engagement of the relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well positioned to reach diverse populations and contribute significantly to the NIAID research agenda.
The phenomenal scientific advances in HIV/AIDS research over the past 30 years have in large part been due to NIAID's high-impact therapeutic and prevention studies being performed by its clinical trials units (CTUs). The Chicago CTU will continue to respond rapidly to emerging clinical research needs, engage constituents, and identify more effective treatment and prevention strategies.
|Chow, Felicia C; Makanjuola, Akintomiwa; Wu, Kunling et al. (2018) Physical activity is associated with lower odds of cognitive impairment in women but not men living with HIV infection. J Infect Dis :|
|Jennings, Cheryl; Wager, Carrie G; Scianna, Salvatore R et al. (2018) Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage. J Clin Microbiol 56:|
|Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524|
|Wyles, David L; Kang, Minhee; Matining, Roy M et al. (2018) Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis 5:ofy103|
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Gianella, Sara; Marconi, Vincent C; Berzins, Baiba et al. (2018) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr 79:e112-e114|
|Robertson, K; Oladeji, B; Jiang, H et al. (2018) HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis :|
|Taiwo, Babafemi O; Zheng, Lu; Stefanescu, Andrei et al. (2018) ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 66:1689-1697|
|Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351|
Showing the most recent 10 out of 145 publications